MediWound (MDWD)
(Delayed Data from NSDQ)
$17.70 USD
+1.35 (8.26%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $17.73 +0.03 (0.17%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDWD 17.70 +1.35(8.26%)
Will MDWD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDWD
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
MDWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Other News for MDWD
MediWound’s NexoBrid Triumphs in Burn Care Study
MediWound Announces Positive Results from the U.S. NexoBrid? Expanded Access Protocol (NEXT)
MediWound announces results from NexoBrid Expanded Access Protocol
MediWound to Report Second Quarter 2024 Financial Results
MediWound Announces Publication of the EscharEx? Phase II ChronEx Study Results for Venous Leg Ulcers